Buchumschlag

Comparative Safety of Ibrutinib Versus Zanubrutinib in Patients With Chronic Lymphocytic Leukemia: A Prospective Cohort Study

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Fuli Fan, Xiaodan Liu, Zhan Su, Saisai Li, Chuanlei Wang, Shibo Wang, Shuxia Cui, Yuting Yan
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Hematological Oncology
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study
von: Ernesto Vigna, et al.
Veröffentlicht: (2025)

Clinical Outcomes in Double‐Exposed Chronic Lymphocytic Leukemia Patients in Italy
von: Francesco Autore, et al.
Veröffentlicht: (2026)

Zanubrutinib in Hairy Cell Leukemia Variant: Clinical Report and Overview of BTK Inhibition in Variant Disease
von: A. Bernardelli, et al.
Veröffentlicht: (2026)

CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia
von: Marilisa Galasso, et al.
Veröffentlicht: (2024)

Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B‐Cell Lymphoma
von: Meirav Kedmi, et al.
Veröffentlicht: (2024)

Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia
von: Georgio Medawar, et al.
Veröffentlicht: (2026)

Fixed Duration Ibrutinib‐Venetoclax, a Redefinition of the CLL Treatment Landscape
von: Stefano Molica, et al.
Veröffentlicht: (2025)

Acalabrutinib in High‐Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real‐Life Experience
von: Idanna Innocenti, et al.
Veröffentlicht: (2025)

Treatment‐Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De‐Escalation: 96‐Week Update of the DANTE Study
von: Alessandra Iurlo, et al.
Veröffentlicht: (2025)

Different Epidemiology of Invasive Pulmonary Aspergillosis in Acute Lymphoblastic Leukemia in Comparison With Acute Myeloid Leukemia: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda
von: C. Cattaneo, et al.
Veröffentlicht: (2025)

Comparative Effectiveness of R‐miniCOMP Versus R‐miniCHOP in Older Non‐Fit Patients With Diffuse Large B‐Cell Lymphoma: Insights From a “Fondazione Italiana Linfomi” Cohort Study
von: Alberto Bavieri, et al.
Veröffentlicht: (2025)

Ibrutinib Dose Adjustment Does Not Impair Treatment Outcome in Mantle Cell Lymphoma: An Italian Real‐Life Multicenter Experience. Results From the REDOT_MCL Study
von: Francesca Maria Quaglia, et al.
Veröffentlicht: (2026)

The Efficacy and Safety of the Addition of Mitoxantrone Hydrochloride Liposome in Conditioning Regimen for High‐Risk Acute Myeloid Leukemia
von: Xiaoyu Zhang, et al.
Veröffentlicht: (2025)

Clinical Outcomes of CD7 CAR‐T Cell Therapy in Relapsed or Refractory T‐Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Patients
von: Jinyan Xiao, et al.
Veröffentlicht: (2025)

Exploratory Analysis of Practical Predictive Indices for the Efficacy of Mogamulizumab in Patients With Aggressive Adult T‐Cell Leukemia‐Lymphoma
von: Yutaka Shimazu, et al.
Veröffentlicht: (2025)

Gene Expression Profiling in Acute Myeloid Leukemia Patient Subgroups With High and Low Sensitivity Toward SYK Inhibitors
von: Marte Karen Brattås, et al.
Veröffentlicht: (2025)

Nodular Lymphocyte‐Predominant Hodgkin Lymphoma: Update on Biology and Treatment
von: Peter Borchmann, et al.
Veröffentlicht: (2025)

TP53 ‐Mutated Acute Myeloid Leukemia: Unanswered Questions
von: Antonella Bruzzese, et al.
Veröffentlicht: (2025)

International Cost‐Effectiveness Analysis of Nivolumab Versus Brentuximab Vedotin for Patients With Advanced‐Stage Classic Hodgkin's Lymphoma
von: Youwen Zhu, et al.
Veröffentlicht: (2026)

A Multicenter Real‐World Retrospective Study for Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, and Prednisolone for Previously Untreated Patients With CD30‐Positive Adult T‐Cell Leukemia‐Lymphoma
von: Masahito Tokunaga, et al.
Veröffentlicht: (2025)

Trends in Incidence and Survival of Patients With Primary Effusion Lymphoma in the United States: A Population Based Cohort Study
von: John L. Vaughn, et al.
Veröffentlicht: (2026)

The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non–Secretory Relapse—A Retrospective Cohort Study
von: Iuliana Vaxman, et al.
Veröffentlicht: (2026)

Survival Benefit of Relmacabtagene Autoleucel Versus Usual Care in Relapsed/Refractory Follicular Lymphoma: A Matching‐Adjusted Indirect Analysis
von: Fenghua Gao, et al.
Veröffentlicht: (2025)

Correction to “Isocitrate Dehydrogenase 2 Mutation Promotes Cytarabine Resistance in Acute Myeloid Leukemia by Warburg Effect”
Veröffentlicht: (2025)

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate‐1‐Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI)
von: Paola Guglielmelli, et al.
Veröffentlicht: (2026)

MicroRNA Profiling of Bone Marrow Plasma Extracellular Vesicles in Multiple Myeloma, Extramedullary Disease, and Plasma Cell Leukemia
von: Jana Gregorova, et al.
Veröffentlicht: (2025)

Follicular Lymphoma: Current Therapeutic Landscape and Future Prospects
von: Emil Kumar, et al.
Veröffentlicht: (2025)

Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor‐Naïve Patients With Myelofibrosis From the Multicenter, Open‐Label, Phase 2 Study (REFINE)
von: Francesco Passamonti, et al.
Veröffentlicht: (2026)

Real‐World Data Analysis on Early Mortality in Chinese Multiple Myeloma Patients: Analysis of 1093 Patients During a 15‐Year Period
von: Xue Yang, et al.
Veröffentlicht: (2025)

RETRACTION: Burkitt Lymphoma Versus Diffuse Large B‐Cell Lymphoma: A Practical Approach
Veröffentlicht: (2026)

Comprehensive Characterization of Overt Myelofibrosis in an Asian Cohort: Phenotype, Mutation Landscape and Discordance Among Scoring Systems
von: Yu‐Sung Chang, et al.
Veröffentlicht: (2025)

Real World Incidence and Etiology of Infectious Complications in Adults With Ph‐Negative Acute Lymphoblastic Leukemia Treated With the Pediatric‐Inspired GIMEMA LAL1913 Program. A Campus All Study
von: Patrizia Zappasodi, et al.
Veröffentlicht: (2025)

Early Detection and Central Nervous System Prophylaxis in Patients With High‐Risk Features of Primary Lymphoma of the Female Genital Tract: The Key to Improved Prognosis
von: Bingyi Wang, et al.
Veröffentlicht: (2025)

Adaptation and Performance of the Self‐Report‐Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) Cohort
von: James R. Cerhan, et al.
Veröffentlicht: (2025)

A Novel Prognostic Score for Disease Progression and Mortality in Patients With Newly Diagnosed Primary Large B‐Cell Lymphoma of Immune‐Privileged Sites
von: Ganggang Wang, et al.
Veröffentlicht: (2025)

Belumosudil in the Management of Heavily Pretreated Prolonged Chronic GVHD: A Retrospective Multicenter Real‐World Study
von: Ben Varon, et al.
Veröffentlicht: (2026)

Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study
von: Pallawi Torka, et al.
Veröffentlicht: (2025)

Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta‐Analysis
von: Lucio N. Gordan, et al.
Veröffentlicht: (2025)

Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High‐Dose Cytarabine‐Based Chemotherapy as Second‐Line Treatments for Relapsed or Refractory Diffuse Large B‐Cell Lymphoma
von: Yoshikazu Ikoma, et al.
Veröffentlicht: (2025)

NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort
von: Calogero Vetro, et al.
Veröffentlicht: (2026)